<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877678</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0363</org_study_id>
    <nct_id>NCT04877678</nct_id>
  </id_info>
  <brief_title>Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis</brief_title>
  <official_title>Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis: A Randomized, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 4 study to evaluate the the efficacy of second generation antihistamine on&#xD;
      cough outcomes in cough patients with allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, placebo controlled trial in which a total of 78&#xD;
      participants who have cough (≥ 3 weeks) and symptoms of allergic rhinitis will be enrolled.&#xD;
      Study participants will be randomly assigned to either active treatment or placebo group. The&#xD;
      subjects in active treatment groups will be treated with daily oral bepotastine for 2 weeks,&#xD;
      while those in placebo group will take identical-looking tablets. The efficacy of bepotastine&#xD;
      will be assessed at the end of 2-week intervention using leicester cough questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-blind, Placebo Controlled Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Allocation of medication is conducted by an independent physician who is not a co-investigator of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Leicester Cough Questionnaire (LCQ)</measure>
    <time_frame>At baseline, and at 2 weeks of treatment</time_frame>
    <description>The total score range of Leicester Cough Questionnaire is from 3 to 21. A higher score indicates a better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) of cough</measure>
    <time_frame>At baseline, and at 2 weeks of treatment</time_frame>
    <description>The visual analogue scale of cough ranges from 0-100. A higher score indicates more severe cough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough hypersensitivity questionnaire (CHQ)</measure>
    <time_frame>At baseline, and at 2 weeks of treatment</time_frame>
    <description>The total score of cough hypersensitivity questionnaire ranges from 0-23. A higher score indicates a greater number of sensations or triggers associated with cough (or a higher degree of cough hypersensitivity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-nasal outcome test -22 (SNOT-22)</measure>
    <time_frame>At baseline, and at 2 weeks of treatment</time_frame>
    <description>The total score of sino-nasal outcome test -22 ranges from 0-110. A higher score indicates worse quality of life related to nasal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) of globus pharyngeus</measure>
    <time_frame>At baseline, and at 2 weeks of treatment</time_frame>
    <description>The visual analogue scale of globus pharyngeus ranges from 0-100. A higher score indicates more severe sensation of globus pharyngeus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily cough severity</measure>
    <time_frame>daily assessment</time_frame>
    <description>The scale of daily cough severity ranges from 0-10. A higher score indicates more severe cough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>during 2 weeks of treatment</time_frame>
    <description>Rate of adverse events in participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective cough frequency</measure>
    <time_frame>At baseline, and at 2 weeks of treatment</time_frame>
    <description>24-hour objective cough frequency will be measured using the Hyfe Cough Tracker, a smartphone application-based cough monitoring. The measurement is optional and will be done in patients who agree to measure it.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with bepotastine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be treated with identical looking placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine</intervention_name>
    <description>10 mg Bepotastine, twice a day</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Beposta B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical looking placebo, twice a day</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Had a cough for at least 3 weeks (score of ≥30 mm on the VAS)&#xD;
&#xD;
          2. History or allergic rhinitis confirmed with skin prick test or serum specific IgE test&#xD;
             AND current one or more symptoms of allergic rhinitis (runny nose, obstruction,&#xD;
             sneezing, nasal itching)&#xD;
&#xD;
          3. Provided written informed consent&#xD;
&#xD;
          4. Were willing and able to comply with the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current smoker or individuals who have smoked within the past 1 month prior to study&#xD;
             entry&#xD;
&#xD;
          2. Sings of coexisting respiratory diseases requiring active treatment such as fever,&#xD;
             chills, wheezing, dyspnea, or purulent sputum&#xD;
&#xD;
          3. Currently under allergen immunotherapy&#xD;
&#xD;
          4. 1) Allergic rhinitis or chronic rhinosinusitis under treatment with intranasal&#xD;
             corticosteroids (INS) or leukotriene receptor antagonist (LTRA) or 2) allergic&#xD;
             rhinitis requiring treatment with INS or LTRA&#xD;
&#xD;
          5. Treatment with an angiotensin converting enzyme (ACE)-inhibitor within 4 weeks prior&#xD;
             to the enrollment&#xD;
&#xD;
          6. Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) &lt; 0.7 or FEV1&#xD;
             % of predicted &lt; 80% within 1 month prior to enrollment&#xD;
&#xD;
          7. Abnormal findings on chest x-ray related to cough within 1 month prior to enrollment&#xD;
&#xD;
          8. Diagnosis or treatment of bronchial asthma or COPD within 1 year of the enrollment&#xD;
&#xD;
          9. Clinically significant medical conditions possibly affecting evaluation of cough and&#xD;
             nasal symptoms&#xD;
&#xD;
         10. History of hypersensitivity or severe adverse reaction to antihistamines&#xD;
&#xD;
         11. Unable to fill in the questionnaires (blindness, unable to read)&#xD;
&#xD;
         12. Unable to provide informed consent&#xD;
&#xD;
         13. History of taking following medication within 2 weeks of the enrollment; LTRA, nasal&#xD;
             decongestants, intranasal corticosteroids (INS), systemic corticosteroids, antitussive&#xD;
             agents (OTCs, codeine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo-Jung Song</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Woo-Jung Song</last_name>
    <phone>82-2-3010-3288</phone>
    <email>swj0126@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji-Hyang Lee</last_name>
    <phone>82-2-3010-1821</phone>
    <email>gogoportia@gmail.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Woo-Jung Song</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cough, allergic rhinitis, antihistamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bepotastine besilate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

